{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:20:48Z","timestamp":1791861648091,"version":"4.3.4"},"reference-count":0,"publisher":"Sociedad Espanola de Quimioterapia","issue":"Suppl1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Quimioter"],"abstract":"<jats:p>Cefiderocol is a new siderophore cephalosporin with potent in vitro activity against gram-negative bacilli including Enterobacterales that produce all kinds of carbapenemases and non-fermenting Gram-negative with difficult-to-treat resistance. As a \u03b2-lactam, its efficacy is optimized in extended-perfusion and requires dose adjustment in renal dysfunction and hyperclearance. Its efficacy has been validated in three clinical trials, one of them in the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. The clinical trial aimed at difficult-to-treat gram-negatives achieved the clinical and microbiological target, but the increase in mortality observed in the cefiderocol arm makes it necessary to demonstrate efficacy in real clinical practice. Cefiderocol is a good option among the new \u03b2-lactams for the treatment of pneumonia caused by Gram-negative bacilli carbapenem-resistant.<\/jats:p>","DOI":"10.37201\/req\/s01.07.2022","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T07:26:27Z","timestamp":1651303587000},"page":"31-34","source":"Crossref","is-referenced-by-count":22,"title":["Cefiderocol"],"prefix":"10.37201","volume":"35","author":[{"given":"Mar\u00eda Cruz","family":"Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Montufar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Blandino-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"23328","published-online":{"date-parts":[[2022,4,22]]},"container-title":["Revista Espa\u00f1ola de Quimioterapia"],"original-title":[],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T07:46:41Z","timestamp":1651650401000},"score":1,"resource":{"primary":{"URL":"https:\/\/seq.es\/abstract\/rev-esp-quimioter-2022-april-07\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":0,"journal-issue":{"issue":"Suppl1","published-online":{"date-parts":[[2022,4,22]]},"published-print":{"date-parts":[[2022,4,22]]}},"URL":"https:\/\/doi.org\/10.37201\/req\/s01.07.2022","relation":{},"ISSN":["0214-3429","1988-9518"],"issn-type":[{"value":"0214-3429","type":"print"},{"value":"1988-9518","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]}}}